Notice: This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsTrends JUNS vs. AEHAW, PHVS, PBMWW, LLY, NVO, JNJ, ABBV, MRK, AZN, and NVSShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Aesther Healthcare Acquisition (AEHAW), Pharvaris (PHVS), Psyence Biomedical (PBMWW), Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), AstraZeneca (AZN), and Novartis (NVS). Jupiter Neurosciences vs. Aesther Healthcare Acquisition Pharvaris Psyence Biomedical Eli Lilly and Company Novo Nordisk A/S Johnson & Johnson AbbVie Merck & Co., Inc. AstraZeneca Novartis Jupiter Neurosciences (NASDAQ:JUNS) and Aesther Healthcare Acquisition (NASDAQ:AEHAW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking. Which has better earnings & valuation, JUNS or AEHAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJupiter NeurosciencesN/AN/AN/AN/AN/AAesther Healthcare AcquisitionN/AN/AN/AN/AN/A Do analysts prefer JUNS or AEHAW? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Aesther Healthcare Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor JUNS or AEHAW? Jupiter Neurosciences received 1 more outperform votes than Aesther Healthcare Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformJupiter NeurosciencesOutperform Votes1100.00% Underperform VotesNo VotesAesther Healthcare AcquisitionN/AN/A Is JUNS or AEHAW more profitable? Company Net Margins Return on Equity Return on Assets Jupiter NeurosciencesN/A N/A N/A Aesther Healthcare Acquisition N/A N/A N/A Does the media refer more to JUNS or AEHAW? In the previous week, Jupiter Neurosciences had 12 more articles in the media than Aesther Healthcare Acquisition. MarketBeat recorded 12 mentions for Jupiter Neurosciences and 0 mentions for Aesther Healthcare Acquisition. Jupiter Neurosciences' average media sentiment score of 0.94 beat Aesther Healthcare Acquisition's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Jupiter Neurosciences Positive Aesther Healthcare Acquisition Neutral SummaryJupiter Neurosciences beats Aesther Healthcare Acquisition on 5 of the 5 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / BookN/A5.094.784.78Net IncomeN/A$151.83M$120.31M$225.60M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$9.73-10.4%N/AN/A$0.00N/A0.005Analyst UpgradeAEHAWAesther Healthcare AcquisitionN/A$0.16+6.2%N/A+22.1%$0.00N/A0.002PHVSPharvaris1.8892 of 5 stars$18.30-0.5%$39.25+114.5%-27.5%$0.00N/A0.0030News CoveragePBMWWPsyence BiomedicalN/A$0.01-7.6%N/AN/A$0.00N/A0.00N/AGap DownLLYEli Lilly and Company4.9933 of 5 stars$780.95-1.0%$1,002.22+28.3%+34.2%$741.37B$40.86B85.4843,000Gap UpNVONovo Nordisk A/S3.7303 of 5 stars$108.42+1.4%$150.40+38.7%-17.9%$486.54B$270.58B34.6163,370Analyst UpgradeNews CoverageGap DownJNJJohnson & Johnson4.8599 of 5 stars$144.72-1.3%$174.73+20.7%-6.7%$348.43B$87.70B21.22131,900ABBVAbbVie4.9377 of 5 stars$172.41-0.6%$203.65+18.1%+15.1%$304.67B$55.53B60.2350,000Analyst ForecastInsider TradeMRKMerck & Co., Inc.4.9889 of 5 stars$100.33-0.8%$129.20+28.8%-7.8%$253.80B$60.12B21.3172,000Analyst DowngradeAZNAstraZeneca4.0479 of 5 stars$66.49-0.1%$89.75+35.0%-1.4%$206.16B$45.81B31.8689,900NVSNovartis3.5241 of 5 stars$97.96-0.4%$121.50+24.0%-1.0%$200.23B$45.44B11.4276,057 Related Companies and Tools Related Companies AEHAW Competitors PHVS Competitors PBMWW Competitors LLY Competitors NVO Competitors JNJ Competitors ABBV Competitors MRK Competitors AZN Competitors NVS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JUNS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
